A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).
Sponsor study identifier
interventional
10
1 country
1
Study Start
June 1, 2018
Actual (reported)Primary Completion
July 30, 2020
Actual (reported)Study Completion
September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study aims to examine the short term and long term safety outcomes of the treatment of PD patients with umbilical cord derived stem cells as indicated by the presence of adverse events that are confirmed to be related to the therapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 1, 2018
Actual (reported)September 23, 2018
Actual (reported)September 25, 2018
Actual (reported)July 30, 2020
Actual (reported)September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection
Side effects will be reported as Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, related TEAEs, severe TEAEs
6 months
Drug Reduction Rate test
6 months
Tractography
6 months
Blood-based biomarkers
6 months
Cerebrospinal Fluid (CSF) based biomarkers
6 months
Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cell Therapy Center, University of Jordan
Amman, 11942, Jordan
Jamali F, Aldughmi M, Khasawneh MW, Dahbour S, Salameh AA, Awidi A. A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study. JMIR Res Protoc. 2021 Oct 22;10(10):e29695. doi: 10.2196/29695.
Abdallah Awidi, MD
Cell Therapy Center
First Submitted
September 23, 2018
First Posted
September 25, 2018
Study Start
June 1, 2018
Actual (reported)Primary Completion
July 30, 2020
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 25, 2021
Record last verified: 2021-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: